Formulary Search Results for: CALCIUM AND VITAMIN D
7.3.2.1 Oral progestogen-only contraceptives - View Category
1.2 Antispasmodics and other drugs altering gut motility - View Category
Prescribing Notes:
In April 2014, following a Europe-wide review, the MHRA issued advice to healthcare professionals relating to the use of domperidone, restricting its use to relief or nausea and vomiting, advising that it should be used at the lowest effective dose for the shortest possible time, and highlighting changes to the contraindications, dosing and duration of treatment of the medicine.
Domperidone is no longer licensed in patients weighing less than 35 kg because of a lack of evidence for benefit.
The full advice from the MHRA and details of the 2019 post-publication note can be accessed here.
13.5.3 Drugs affecting the immune response - View Category
Restrictions:
Restricted to specialist use in accordance with local guidelines for the treatment of moderate to severe atopic dermatitis in adult patients who are candidates for systemic therapy who have failed at least one current systemic immunosuppressant due to intolerance, contraindication or inadequate disease control.
Prescribing Notes:
Following a MHRA review in April 2023, the risk of increased incidence of malignancy, major adverse cardiovascular events (MACE), serious infections, venous thromboembolism (VTE) and mortality, when compared to those treated with tumour necrosis factor (TNF)-alpha inhibitors, were are considered a class effects across JAK inhibitors used for chronic inflammatory disorders and therefore it is advised to avoid prescribing these medicines unless there are no suitable alternatives in patients with the following risk factors:
- age 65 years or older
- current or past long-time smoking
- other risk factors for cardiovascular disease or malignancy
Please see further details of the review here.
8.3.2 Progestogens - View Category
3.1.2.1 Antimuscarinic combination inhalers - View Category
3.7 Mucolytics - View Category
Restrictions:
Restricted to specialist initiation.
Prescribing Notes:
Responsibility for initiation, review and any necessary monitoring rests with specialist service.
16.2 Specific antidotes - View Category
3.1.2 Antimuscarinic bronchodilators - View Category
Restrictions:
For use as a maintenance bronchodilator in COPD. Preferred List use of tiotropium only relates to use in COPD.
Prescribing Notes:
Preferred brand and device:
- Tiogiva®
To prevent confusion, prescribe inhaler devices by brand name.
5.1.10 Antileprotic drugs - View Category
Restrictions:
Restricted to specialist initiation.
Prescribing Notes:
For indications in dermatology please refer to section 13.10.1.2
5.1.12 Quinolones - View Category
Restrictions:
Restricted to use on the advice of a consultant microbiologist or consultant infectious disease physician for patients with acute bacterial skin and skin structure infections (ABSSSI) who have suspected or confirmed polymicrobial infection following treatment failure or when standard antibacterial therapies are not suitable.
Please note: this is a PROTECTED ANTIBIOTIC (see policy here) and relevant paper work should be completed.
Prescribing Notes:
Due to the risk of severe, disabling and potentially permanent adverse events, new restrictions apply to the prescribing of fluoroquinolones.
Please see new MHRA advice (January 2024) and NHSGGC statement (March 2024) for more details.